Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cell Medica Achieves EU Orphan Drug Designation

Published: Tuesday, January 07, 2014
Last Updated: Tuesday, January 07, 2014
Bookmark and Share
Orphan drug designation in the European Union for Cytovir ADV.

Imperial Innovations Group plc has welcomed the announcement from portfolio company Cell Medica that its cell therapy Cytovir ADV has been awarded a positive opinion by the European Medicines Agency’s Committee for Orphan Medicinal Products.

The EU’s Orphan Medicinal Product Designation is designed to promote the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases. The designation also provides eligibility for protocol assistance, possible exemptions or reductions in regulatory fees during development, and ten years of market exclusivity from product launch in the EU.

Cytovir ADV, a novel T cell immunotherapy, targets the treatment of adenovirus infections in patients following a bone marrow transplant. Adenovirus infections are a frequent cause of morbidity and mortality in patients, particularly children, who have received bone marrow transplants.

Cytovir ADV is being investigated as a novel method for transferring adenovirus immunity from the donor to the patient following the bone marrow transplant procedure. These patients are generally profoundly immuno-compromised for a period of six to nine months after the procedure and hence vulnerable to life-threatening infections. Cell Medica is developing a related product, Cytovir CMV, for cytomegalovirus infections in the same patient group.

Cytovir ADV is currently being investigated in the ASPIRE Phase I/II clinical trial under way at the Great Ormond Street Hospital (GOSH) in London.

Maina Bhaman, Director of Healthcare Investments at Innovations, said: “The EU orphan designation for Cytovir ADV, the first for a T cell therapy to treat infections, reflects Cell Medica’s continued leadership in developing cell-based immunotherapies. The orphan status can provide an important competitive advantage to support the company’s commercialization strategy going forward.”

Gregg Sando, Chief Executive Officer of Cell Medica, said: “Cytovir ADV represents a potential breakthrough for the treatment of life-threatening adenovirus infections in children following a bone marrow transplant and we are very excited about the continued progress for this cell therapy. Receiving orphan designation for Cytovir ADV in the European Union is a significant milestone for Cell Medica. The benefits include 10 years of market exclusivity from product launch in the EU as well as fee reductions.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TopiVert Starts Phase I Clinical Trial in Ulcerative Colitis
The Phase I study is being conducted at a specialist centre in London and will report in 2016.
Tuesday, May 19, 2015
Imperial Innovations and Kurma BioFund I conclude £0.93m seed investment in Indigix Ltd
The technology commercialisation and investment company Imperial Innovations Group plc has led a seed investment of £0.93m into its portfolio company Indigix Ltd (Indigix), alongside the Paris-based life science fund Kurma BioFund I.
Wednesday, December 01, 2010
Scientific News
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Neural Networks Adapt to the Presence of a Toxic HIV Protein
HIV-associated neurocognitive disorders (HAND) afflict approximately half of HIV infected patients.
HIV Protein Manipulates Hundreds of Human Genes
Findings search for new or improved treatments for patients with AIDS.
Breaking the Brain’s Garbage Disposal
The children’s ataxia gene problem turned out to be not such a big deal genetically — it was such a slight mutation that it barely changed the way the cells made the protein.
Flesh-Eating Bacteria Work Together
Scientists recently discovered different strains of deadly flesh-eating bacteria working together to spread infection and they now have a better understanding of the role of the toxins they produce. The discovery could change how the illness and other diseases are treated.
Utilizing Antibodies from Ebola Survivors
A collaborative team from The University of Texas Medical Branch at Galveston, Vanderbilt University, The Scripps Research Institute and Integral Molecular Inc. have learned that antibodies in the blood of people who have survived a strain of the Ebola virus can kill various types of Ebola.
Antibiotic Use in Early Life Disrupts Gut Microbiota
The use of antibiotics in early childhood interferes with normal development of the intestinal microbiota, shows research conducted at the University of Helsinki.
Easier Diagnosis for Fungal Infection of the Lungs
A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.
Mitochondrial Troublemakers Unmasked in Lupus
Drivers of autoimmune disease inflammation discovered in the traps of pathogen-capturing white blood cells.
Important Regulator of Immune System Decoded
Plasma cells play a key role in our immune system. Now scientists at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria, and at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia, succeeded in characterizing a central regulator of plasma cell function.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!